Furthermore, EGFR-CAR-NK-92 cells displayed synergistic therapeutic efficacy with cabozantinib toward human renal cell carcinoma (RCC) xenograft models as cabozantinib could improve EGFR and attenuate PD-L1 membrane surface expression in RCC cells. This evidence concerns the gene EGFR and hereditary clear cell renal cell carcinoma.